Skip to Content

Moderna: FDA delaying decision on its shot for adolescents

KION

CAMBRIDGE, Mass. (AP) — U.S. regulators are delaying their decision on Moderna’s COVID-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation. Moderna said Sunday that the U.S. Food and Drug Administration told the company Friday evening that its review could last until January. The company also says it will delay filing a request for emergency-use authorization of a lower dose of the vaccine for 6- to 11-year-olds. Heart inflammation is an exceedingly rare risk of both the Pfizer and Moderna vaccines, and it more commonly seen in young men or boys. Public health officials have repeatedly stressed that COVID-19 itself can cause heart inflammation.

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KION 46 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content